| Literature DB >> 26446786 |
Jingqiu Cui1, Wei Chen2, Jinhong Sun3, Huan Guo3, Rachel Madley3, Yi Xiong3, Xingyi Pan3, Hongliang Wang4, Andrew W Tai4, Michael A Weiss5, Peter Arvan6, Ming Liu7.
Abstract
Upon translocation across the endoplasmic reticulum (ER) membrane, secretory proteins are proteolytically processed to remove their signal peptide by signal peptidase (SPase). This process is critical for subsequent folding, intracellular trafficking, and maturation of secretory proteins. Prokaryotic SPase has been shown to be a promising antibiotic target. In contrast, to date, no eukaryotic SPase inhibitors have been reported. Here we report that introducing a proline immediately following the natural signal peptide cleavage site not only blocks preprotein cleavage but also, in trans, impairs the processing and maturation of co-expressed preproteins in the ER. Specifically, we find that a variant preproinsulin, pPI-F25P, is translocated across the ER membrane, where it binds to the catalytic SPase subunit SEC11A, inhibiting SPase activity in a dose-dependent manner. Similar findings were obtained with an analogous variant of preproparathyroid hormone, demonstrating that inhibition of the SPase does not depend strictly on the sequence or structure of the downstream mature protein. We further show that inhibiting SPase in the ER impairs intracellular processing of viral polypeptides and their subsequent maturation. These observations suggest that eukaryotic SPases (including the human ortholog) are, in principle, suitable therapeutic targets for antiviral drug design.Entities:
Keywords: enzyme inhibitor; mutant; protein processing; protein synthesis; protein trafficking; secretory protein; signal peptidase; viral polypeptide
Mesh:
Substances:
Year: 2015 PMID: 26446786 PMCID: PMC4653672 DOI: 10.1074/jbc.M115.692350
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157